Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma Announces U.S. FDA Approval of ILUMYA™

Posted On: 2018-03-21 07:07:19

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks, after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

"With the approval of ILUMYA™ and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis," said Abhay Gandhi, President and Chief Executive Officer, North America, Sun Pharma. "We are committed to working with all relevant stakeholders to make ILUMYA™ available to appropriate people with plaque psoriasis."

The FDA approval of ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multicenter, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 926 adult patients were treated with ILUMYA™ (N=616) or placebo (N=310). Results from these studies were published in The Lancet in July 2017, with primary endpoints presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress.

Both Phase-3 studies met the primary efficacy endpoints, demonstrating significant clinical improvement with ILUMYA™ 100 mg compared to placebo when measured by at least 75 percent of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses.

Of the patients in the reSURFACE 1 study 74 percent (229 patients) achieved 75 percent skin clearance at week 28 after three doses, and 84 percent of patients who continued receiving ILUMYA™ 100 mg maintained PASI 75 at week 64 compared to 22 percent of patients who were re-randomized to placebo. In addition, 69 percent of the patients receiving ILUMYA™ 100 mg who had a PGA score of "clear" or "minimal" at week 28 maintained this response at week 64 compared to 14 percent of patients who were re-randomized to placebo.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.504.7 as compared to the previous close of Rs. 508.85. The total number of shares traded during the day was 409209 in over 3190 trades.

The stock hit an intraday high of Rs. 515.8 and intraday low of 502.8. The net turnover during the day was Rs. 208634257.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

'Spirit of Wipro' Run 2018 Held in 125 Cities across 34 countries

Usha Martin Limited signs agreement to sell steel business to Tata Steel Ltd

SeQuent Scientific Limited to acquire facility for Rs. 46.4 crores

INOX Leisure Ltd commences commercial operations of multiplex at Reliance Mega Mall, Surat

Cipla receives final approval for generic version of Impax Laboratories, Inc.'s Albenza®

Mcleod Russel India Ltd to sell certain specified assets for Rs. 180.7 crore

Shri Anil Kumar Chaudhary assumes position of Chairman at SAIL

Lakshmi Machine Works Ltd board to announce Q2, H1 FY19 results on Oct 22, 2018

Chordia Food Products Ltd gets NCLT nod for demerger

Solara Active Pharma Sciences Ltd to sell API facility at Mahad, India

Tata Steel Limited signs definitive agreements to acquire steel business of Usha Martin Ltd

Galaxy Surfactants receives withdrawal of closure notice from MPCB

Kings Infra Ventures Limited to consider business decisions on Sep 30, 2018

SOFTSOL INDIA LTD board to consider investment proposal on Sep 29, 2018

Biocon's Drug Substance Facility in Bangalore completes US FDA inspection with no observations

Usha Martin Ltd to sell its steel business to Tata Steel

Radico Khaitan Limited contributes Rs 51 lacs for Swachh Bharat Mission of UP Govt

ACC encourages reading and education in Chandrapur District

YES BANK Partners with IATA to Launch IATA EasyPay solution for travel agents in India

Infosys Partners with Google Cloud to Develop Data Native Intelligent Enterprise

Colgate-Palmolive India Ltd board to announce 2nd quarter, H1 FY19 results on Oct 29, 2018

Ravileela Granites Ltd sanctioned Rs. 17.2 crore term loan by SBI

Shri Karnam Sekar appointed Managing Director and Chief Executive Officer of Dena Bank

Automotive Stampings & Assemblies Ltd board to consider Q2 results on Oct 26, 2018

The Lakshmi Mills Company Ltd announces resignation of CFO

DHFL - Update on price fall - Kapil Wadhawan, CMD, DHFL

Shri Gopal Singh Gusain appointed as ED of Union Bank of India

Jio to provide India Cricket content to all Jio users on JIOTV platform

ABB to enhance power quality for India's longest freight train network

CARE reaffirms credit rating of Dhampur Sugar Mills Ltd

Wipro Partners with King's College London and Sheffield Hallam University to strengthen STEM education in the UK

3I Infotech Ltd board to consider Q2, H1 FY18-19 results on Oct 12, 2018

ITD Cementation India Limited wins orders valued at INR 845 Crores

HDFC Bank Ltd board to consider 2nd quarter results on Oct 20, 2018

Pennar Group bags orders worth INR 181 crore

Infosys to Open Technology and Innovation Hub in Arizona and Hire 1000 Workers by 2023

Tijaria Polypipes Ltd bags order of Rs. 35.30 crores

GMR-TERNA JV receives Letter of Award for New Crete airport

TCS Recognized as a Leader in Finance and Accounting Digital Augmentation Suite by Everest Group

Meera Industries Ltd receives order from Bolivia

Sun Pharma announces Australian TGA approval of ILUMYA™

Reliance Industries Ltd updates on KGD6 well

Dion Global Solutions launches Modular Wealth Intelligence Platform

Infosys Recognized as a Microsoft Azure Expert Managed Services Provider

Nagarjuna Fertilizers and Chemicals Ltd extends shut down of plant

Dilip Buildcon Ltd declared L-1 for Indore Metro Rail Project, Phase-I

Gravita expands production capacity of its plant situated at Chittoor, Andhra Pradesh

Graphite India Ltd clarifies on pollution issues at Bengaluru Plant

CARE assigns rating to Pitti Laminations Ltd

GRUH Finance Ltd to consider 2nd quarter results on Oct 29, 2018





Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018